FICPI World Congress –
Trade Related Aspects of IP
Kristin Wall

Toronto, June 7, 2018
Outline

1. IP Related Trade Disputes
2. Trade Agreement Impact on Canadian IP Practice
3. Future Trade Agreement IP Impact?
1. IP Related Trade Disputes
**TRIPS – Tobacco Plain Packaging Dispute**

**Background**

- Australian laws imposed plain packaging requirements and restrictions on trademarks and geographical indications on tobacco products and packaging

- Complaints by Indonesia, Honduras, Dominican Republic, Cuba and Ukraine (suspended) against Australia

- Allegations that measures were inconsistent with Australia’s obligations under GATT 1994, TRIPS agreement and TBT agreement
TRIPS – Tobacco Plain Packaging Dispute

Timeline*

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 20, 2013</td>
<td>Indonesia Requests Consultations with Australia</td>
</tr>
<tr>
<td>Mar. 26, 2014</td>
<td>DSB Establishes a Panel</td>
</tr>
<tr>
<td>June 29, 2016</td>
<td>Final Report Expected “Not Before” the End of 2016</td>
</tr>
<tr>
<td>May 5, 2017</td>
<td>Confidential Draft of Report Leaked</td>
</tr>
<tr>
<td>Sept. 21, 2017</td>
<td>Final Report Expected “Not Before” Q3 of 2017</td>
</tr>
</tbody>
</table>

* Timeline for Indonesia’s complaint. The timelines for the other complaints are similar, except for Ukraine’s complaint which was suspended in May 2015.
**Examples of Australia’s Plain Packaging Laws**

- Prohibition on trademarks and marks generally appearing on retail packaging [*Tobacco Plain Packaging Act 2011 (No. 148,2011)*, s. 20]

- The surfaces of the packaging must not have any decorative ridges, embossing, bulges or other irregularities of shape or texture, or any other embellishments [s. 18(1)(a)]

- All outer surfaces of primary packaging and secondary packaging must be the colour known as Pantone 448C [*Tobacco Plain Packaging Regulations 2011*, Division 2.2.1(2)]
Relevant TRIPS Agreement Provisions

➢ The nature of the goods or services to which a trademark is to be applied shall in no case form an obstacle to registration of the trademark. [TRIPS, Art. 15.4]

➢ The use of a trademark in the course of trade shall not be unjustifiably encumbered by special requirements, such as...use in a special form...[TRIPS, Art. 20]

➢ ...a Member shall not diminish the protection of geographical indications that existed in that Member immediately prior to the date of entry into force of the WTO Agreement. [TRIPS, Art. 24.3]
TRIPS – Tobacco Plain Packaging Dispute

Resolution

➢ May 4, 2017 – Bloomberg reports an unidentified source indicated that the WTO upheld Australia’s right to impose plain packaging label restrictions on the sale of tobacco products as a legitimate public health measure

➢ Panel has not released its report
Background

- Complaint by the European Communities and their member states against Canada

- Allegations that s. 55.2(1) (the “Regulatory Review Exception”) and s. 55.2(2) (the “Stockpiling Exception”) of the Patent Act were not compatible with Canada’s TRIPS obligations
**TRIPS – Pharmaceutical Patents Dispute (DS114)**

**Timeline**

- **Dec. 19, 1997**: EC Requests Consultations with Canada
- **Nov. 11, 1998**: EC Requests Establishment of a Panel
- **Feb. 1, 1999**: DSB Establishes a Panel
- **Mar. 25, 1999**: Director-General Composes the Panel
- **Mar. 17, 2000**: Panel Report Circulated to Members
- **April 7, 2000**: DSB Adopts the Panel Report
- **Oct. 7, 2000**: Deadline for Canada to Implement the DSB’s Recommendations
- **Oct. 23, 2000**: Canada Informs Members it had implemented the DSB’s Recommendations

---

= Actions Taken by the EC  = Actions Taken by Dispute Settlement Body  = Actions Taken by Canada
TRIPS – Pharmaceutical Patents Dispute (DS114)

Relevant Legislation (*Patent Act*)

➢ The Canadian *Patent Act* provided that:

55.2(1) It is not an infringement of a patent for any person to make, construct, use or sell the patented invention solely for uses reasonably related to the development and submission of information required under any law of Canada…that regulates the manufacture, construction, use or sale of any product (*Regulatory Review Exception*); and

55.2(2) It is not an infringement of a patent for any person who makes, constructs, uses or sells a patented invention in accordance with subsection (1) to make, construct or use the invention, during the applicable period provided for by the regulations, for the manufacture and storage of articles intended for sale after the date on which the term of the patent expires. (*Stockpiling Exception*)
Relevant TRIPS Agreement Provisions

➢ A patent shall confer on its owner the following exclusive rights:

(a) where the subject matter of a patent is a product, to prevent third parties not having the owner’s consent from the acts of: making, using, offering for sale, selling, or importing for those purposes that product… [Art. 28.1(a)]

➢ Members may provide **limited exceptions** to the exclusive rights conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties. [Art. 30]
TRIPS – Pharmaceutical Patents Dispute (DS114)

TRIPS Agreement Article 30

➢ Three criteria required to be met to qualify for an exception:

(i) the exception must be “limited”;

(ii) the exception must not “unreasonably conflict with normal exploitation of the patent”; and

(iii) the exception must not “unreasonably prejudice the legitimate interests of the patent owner.”
Stockpiling Exception - s. 55.2(2)

- **Panel Report**

  i) **The exception must be limited.** - The right to exclude “making” and “using” provides protection during the entire term of the patent by cutting off the supply of competing goods at the source. s. 55.2(2) removes that protection entirely during the last six months of the patent term.

  ii) and iii) – In light of the finding concerning i), the panel did not consider parts ii) and iii) to an Art. 30 exception.
Resolution - Stockpiling

➢ Panel concluded that the stockpiling exception constitutes a substantial curtailment of the exclusionary rights required to be granted to patent owners under Art. 28.1 of TRIPS

➢ Canada was given until October 7, 2000 to implement the recommendations and rulings of the DSB

➢ On October 7, 2000, the Governor General in Council revoked the Manufacturing and Storage of Patented Medicines Regulations

➢ s. 55.2(2) of the Patent Act was repealed by Bill S-17 (An Act to amend the Patent Act) on June 14, 2001
Resolution – Regulatory Review Exception

➢ Panel found that s. 55.2(1) satisfies all three conditions of Art. 30 and thus is not inconsistent with Canada’s obligations under Art. 28.1 of the TRIPS Agreement

➢ The Regulatory Review Exception is still in force today
NAFTA - Eli Lilly v. Canada

Background

➢ Eli Lilly owns Canadian patents relating to atomoxetine (STRATTERA®) and olanzapine (ZYPREXA®)

➢ Patents invalidated for lack of utility / failing to fulfill the “promise” of the patent

➢ Claim for $500 million against Canada for violating obligations to foreign investors under NAFTA

➢ Application of the “promise doctrine” by Canadian Courts is “arbitrary in its application” and “discriminatory in its effects”
NAFTA - Eli Lilly v. Canada

Timeline

- Notice of Arbitration: Nov. 7, 2012
- Statement of Defence: June 30, 2014
- Counter-Memorial: Jan. 27, 2015
- Rejoinder: Dec. 8, 2015
- Tribunal Releases Award: Mar. 17, 2017
- SCC’s NEXIUM Decision: June 30, 2017
Promise Doctrine

Where the specification does not promise a specific result, no particular level of utility is required; a “mere scintilla” of utility will suffice. However, where the specification sets out an explicit “promise”, utility will be measured against that promise. The question is whether the invention does what the patent promises it will do.

– Layden-Stevenson J.A.

Eli Lilly Canada Inc. v. Novopharm Ltd. (olanzapine), 2010 FCA 197
NAFTA - Eli Lilly v. Canada

Relevant NAFTA Provisions

➢ No Party may directly or indirectly nationalize or expropriate an investment of an investor of another Party in its territory or take a measure tantamount to nationalization or expropriation of such an investment… [Art. 1110]

➢ Each Party shall accord to investments of investors of another Party treatment in accordance with international law, including fair and equitable treatment and full protection and security [Art. 1105]

➢ …[E]ach Party shall make patents available for any inventions, …provided that such inventions are new, result from an inventive step and are capable of industrial application. [Art. 1709]
Resolution

➢ Claimant’s claim is dismissed in its entirety

➢ i) No Dramatic Change in Law

➢ ii) Promise Doctrine Applied by Courts not Arbitrary

➢ iii) Promise Doctrine Applied by Courts not Discriminatory Against Pharmaceutical Patents
NAFTA - Eli Lilly v. Canada

Promise Doctrine

Where the specification does not promise a specific result, no particular level of utility is required; a “mere scintilla” of utility will suffice. However, where the specification sets out an explicit “promise”, utility will be measured against that promise. The question is whether the invention does what the patent promises it will do.

– Layden-Stevenson J.A.

Eli Lilly Canada Inc. v. Novopharm Ltd. (olanzapine), 2010 FCA 197

The Promise Doctrine is not the correct method of determining whether the utility requirement under s. 2 of the Patent Act is met. First, courts must identify the subject-matter of the invention as claimed in the patent. Second, courts must ask whether that subject-matter is useful — is it capable of a practical purpose (i.e. an actual result)

– Rowe J.J.

AstraZeneca Canada Inc. v. Apotex Inc. (esomeprazole), 2017 SCC 36
2. Trade Agreement Impact on Canadian IP Practice
Trade Agreement Impact on Canadian IP Rights

- **Extension of patent term** (17 years from date of issue → 20 years from date of filing)

- **Compulsory licensing abolished** (Bill C-91 – Feb. 15, 1993)

- **PM(NOC) Regulations introduced** (SOR/93-133 – Mar. 12, 1993)

- **Pharmaceutical data protection** (*Food and Drug Regulations*, s. C.08.004.1)
CETA (2017 - provisionally)

➢ Bilateral trade agreement between Canada and the EU

➢ Significant changes relating to pharmaceutical patents
CETA – Key Reforms

1) Patent Term Restoration:
   - via Certificates of Supplementary Protection ("CSP")
   - Capped at 2 years

2) “Single Track” Patented Medicines (Notice of Compliance) Regulations [PM(NOC)]:
   - In rem litigation by way of action in 24 months

3) Data Protection:
   - Minimum 6 year no-filing period
   - Minimum of 8 year market exclusivity
CETA – CSP Eligibility (Overview)

CSP eligibility based on 3 key components:

✓ Timing
✓ Medicinal Ingredient
✓ Patent
CETA – “Single Track PMNOC” (Overview)

Before CETA
- Summary proceedings under the PM(NOC) Regulations
- No in rem patent findings
- Alternative remedies under the Patent Act
- Innovators lack effective appeal rights
- S. 8 liability limited to generic damages suffered during specified period

After CETA
- Full actions under the PM(NOC) Regulations
- Patent findings in rem
- Action estoppel, subject to lack of “reasonable basis”
- All litigants provided with “equivalent and effective” rights of appeal
- S. 8 liability for damages suffered after specified start date
3. Future Trade Agreement IP Impact?
NAFTA Re-negotiation

IP Negotiating Objectives?

➢ July 17, 2017 – Office of the United States Trade Representative releases list of NAFTA negotiation objectives. IP objectives include:

i) ensuring provisions governing IP rights reflect a standard of protection similar to that found in U.S. law;
ii) preventing the improper use of a country’s system for protecting or recognizing GIs
iii) provide strong civil, administrative, and criminal enforcement mechanisms

➢ August 14, 2017 – Foreign Affairs Minister Chrystia Freeland releases Canada’s list of key demands. IP demands include:

i) none!
NAFTA Re-negotiation

Potential Differing Standards of IP Protection?

➢ Patent term restoration
➢ Data protection
➢ Orphan drug legislation
➢ Geographical indications
NAFTA Re-negotiation

Upcoming Events

➢ 8th Round of Formal Talks – on hold

➢ Recent high level talks occurred in Washington D.C.

➢ Officials expected to reconvene in early May

➢ November 2018 – U.S. midterm elections

➢ July 2018 – Mexican presidential election
**CP-TTP**

**Background**

- **Original TPP** – Multilateral agreement between 12 Pacific Rim countries (Canada, U.S., Japan, Australia, New Zealand, Peru, Chile, Mexico, Singapore, Brunei, Vietnam, Malaysia)

- **February 4, 2016** – TPP signed (never ratified)

- **January 23, 2017** - President Trump withdraws U.S. from the TPP

- **Late 2017** – Remaining countries attempt to salvage TPP without U.S. involvement

- **January 2018** – CP-TTP negotiations conclude with agreement. Various IP provisions added at the U.S.’s request are suspended

- **March 8, 2018** – CP-TTP signed
**Examples of IP Provisions - TPP vs. CP-TPP**

<table>
<thead>
<tr>
<th>TPP</th>
<th>CP-TTP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extension of copyright term</td>
<td>Patent grace-period</td>
</tr>
<tr>
<td>Patent term adjustment</td>
<td>Limitations on GI rights</td>
</tr>
<tr>
<td>Patent grace-period</td>
<td>Stronger trade secret protection</td>
</tr>
<tr>
<td>8-year biologic protection (with flexibility)</td>
<td></td>
</tr>
<tr>
<td>Limitations on GI rights</td>
<td></td>
</tr>
<tr>
<td>Stronger trade secret protection</td>
<td></td>
</tr>
</tbody>
</table>
U.S. Returning to TPP?

➢ April 12, 2018 – President Trump asks trade officials to explore the possibility of the U.S. rejoining the TPP

Would only join TPP if the deal were substantially better than the deal offered to Pres. Obama. We already have BILATERAL deals with six of the eleven nations in TPP, and are working to make a deal with the biggest of those nations, Japan, who has hit us hard on trade for years!

8:15 PM - 12 Apr 2018


**CP-TPP**

**U.S. CP-TPP Concession Targets?**

Suspended Provisions include:

- **Extension of Copyright Term** – i) Natural persons = life of author + 70 years; ii) Otherwise = 70 years from publication or 70 years from creation (if no publication within 25 years of creation)

- **Patent Term Adjustment** – Means to adjust the term of the patent to compensate for unreasonable granting authority delays

- **Biologic Data Protection** – 8 years of protection, or 5 years plus “other measures”
NORTON ROSE FULBRIGHT
Disclaimer

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to ‘Norton Rose Fulbright’, ‘the law firm’ and ‘legal practice’ are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together ‘Norton Rose Fulbright entity/entities’). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a ‘partner’) accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.